In the bone metastatic tumor fraction, we observed an increased average expression of glutamine transporter SLC1A5 (ASCT2), glutamine utilizing enzymes GLS, glutamine-fructose-6-phosphate transaminase (GFPT1), phosphoribosyl pyrophosphate amidotransferase (PPAT), glutamine synthetase (GLUL), and glycolytic enzyme hexokinase (HK2) relative to the benign or distal bone marrow (BM) fraction. This evidence concerns the gene SLC1A5 and metastatic neoplasm.